Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Forecasts Loss for Fiscal 2008 After Flurry of M&A Moves

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical forecasted losses for fiscal year 2008 due in large part to recent M&A activity, and operating income and ordinary income fell in fiscal year 2007, the company announced

You may also be interested in...



Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug

TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said

Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug

TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said

Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise

TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel